Drug-induced thrombocytopenia
What it is
A low platelet count may be the work of a drug the patient takes. The best described form is heparin induced thrombocytopenia (HIT), which comes in two types that differ in frequency, onset, mechanism and outcome. Type 1 HIT comes from a direct interaction between heparin and platelets, for example heparin directly induces platelet aggregation, with no antibodies involved. Type 2 HIT comes from autoantibodies against a complex composed of platelet factor 4 (PF4) and heparin. Those autoantibodies induce thrombocytopenia, through removal of antibody-coated platelets by macrophages and the reticuloendothelial system and through consumption of platelets in thrombi, and they induce arterial and venous thrombosis as well, by an unclear mechanism that appears to involve platelet activation.
Causes and risk
Type 1 HIT is the commoner of the two, at about 10-20%. Type 2 HIT occurs in 1-5% of those given UFH and in 0.1-1% of those given LMWH. Other than heparin, some medications are frequently reported to cause drug-induced thrombocytopenia, so the drug list is checked when a low count is found.
How it presents
Type 1 HIT starts within the first 5 days of treatment. Its fall in platelets is moderate, above 100,000 platelets/uL, and clinically insignificant. Type 2 HIT starts on day 5-14. Its fall is massive, below 100,000 platelets/uL, or a decrease of more than 50% compared to baseline, and clinically significant. Bleeding is rare, because the platelet nadir is usually above 20,000 platelets/uL. Thrombosis is what matters: venous thrombi are more common than arterial ones, involving the legs (deep vein thrombosis), the cardiac vessels (myocardial infarction), and the skin.